The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages.
Participants will be asked to take an extra blood test, which will be analyzed further in the lab.
Have proven Lynch Syndrome (MMR-gene or EPCAM mutation), or have a proven microsatellite instability high (MSI-H)tumor;
Are at least 18 years old; Have been diagnosed with any form of cancer at the time of inclusion, but have had no treatment yet;
Have granted informed consent to participate in this study.
Are unwilling to undergo extra blood sampling;
Are under the age of 18;
Have no newly diagnosed tumors at time of inclusion;
Have been treated for their tumor at time of inclusion;
Single group
Blood Product
Diagnostic testAn (extra) blood test will be done on participants. This will be analyzed for circulating tumor DNA (ctDNA) via a multi-omics approach.
Estimated ctDNA fractions in blood
ctDNA presence will be measured against a (presently not specified) threshold, creating a divide between 'detectable' and 'non-detectable'.
Tumor pathology
Tumor pathology will be revised to later compare with estimated ctDNA presence.
Click on the lead sponsor to view all of their trials.
Erasmus Medical Center
Lead sponsor
Dutch Cancer Society
Collaborator
Leiden University Medical Center
Collaborator
